Canadian Pharmaceutical Company Lexaria Bioscience Corp Plunges 27.4% in Early Trading
Deep News
Sep 26, 2025
Canadian pharmaceutical company Lexaria Bioscience Corp (LEXX) fell 27.4% in early trading after the company announced the termination of its $5 million stock sales agreement with JonesTrading. This decision reflects the company's strategic adjustment to optimize its capital structure and market positioning.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.